Table VI.
Regression Results for the Four Drugs
| Terms | Coefficients | p value |
|---|---|---|
| Genistein | ||
| PEG400 | 101.35 | a |
| Capmul PG-8 | 6.18 | a |
| Labrasol | 53.56 | a |
| Polysorbate 80 | 74.82 | a |
| PEG400*Capmul PG-8 | −36.00 | 0.000 |
| PEG400*Labrasol | 1.01 | 0.863 |
| PEG400*Polysorbate 80 | 7.91 | 0.188 |
| Capmul PG-8*Labrasol | −20.58 | 0.002 |
| Capmul PG-8*Polysorbate 80 | −37.26 | 0.000 |
| Labrasol*Polysorbate 80 | −1.16 | 0.843 |
| R2 | 0.9973 | |
| Probucol | ||
| Miglyol 812 | 158.20 | a |
| Capmul PG-8 | 184.96 | a |
| Labrafil M1944CS | 98.15 | a |
| Polysorbate 80 | 7.15 | a |
| Miglyol 812*Capmul PG-8 | 14.58 | 0.755 |
| Miglyol 812*Labrafil M1944CS | 52.47 | 0.270 |
| Miglyol 812*Polysorbate 80 | 127.83 | 0.013 |
| Capmul PG-8*Labrafil M1944CS | 69.56 | 0.149 |
| Capmul PG-8*Polysorbate 80 | −5.48 | 0.907 |
| Labrafil M1944CS*Polysorbate 80 | 52.20 | 0.272 |
| R2 | 0.8853 | |
| Nifedipine | ||
| PEG400 | 89.67 | a |
| Capmul PG-8 | 27.04 | a |
| Labrasol | 73.83 | a |
| Cremophor RH40 | 78.11 | a |
| PEG400*Capmul PG-8 | 23.68 | 0.018 |
| PEG400*Labrasol | 22.09 | 0.025 |
| PEG400*Cremophor RH40 | 20.64 | 0.035 |
| Capmul PG-8*Labrasol | −7.83 | 0.397 |
| Capmul PG-8*Cremophor RH40 | −17.28 | 0.072 |
| Labrasol*Cremophor RH40 | −11.80 | 0.208 |
| R 2 | 0.9861 | |
| Indomethacin | ||
| PEG400 | 144.17 | a |
| Capmul PG-8 | 42.79 | a |
| Labrasol | 115.23 | a |
| Cremophor RH40 | 120.76 | a |
| PEG400*Capmul PG-8 | 59.49 | 0.001 |
| PEG400*Labrasol | 25.90 | 0.083 |
| PEG400*Cremophor RH40 | 12.83 | 0.374 |
| Capmul PG-8*Labrasol | 11.37 | 0.430 |
| Capmul PG-8*Cremophor RH40 | 16.59 | 0.254 |
| Labrasol*Cremophor RH40 | −4.94 | 0.730 |
| R 2 | 0.9839 | |
aNot applicable to linear terms, which must be included in the model